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Introduction 
It is fundamentally understood that the differential 
expression of a distinct assemblage of proteins is 
attributed to cancer cells’ ability to develop, proliferate, 
and metastasize (1). Indeed, increasing evidence has 
revealed that deregulated protein synthesis plays a 
critical role in cell transformation (2-4). Irregular protein 
expression may not only be due to gene mutations and 
altered transcription, but also through transformed 
posttranscriptional machineries such as mRNA storage, 
transport, splicing, translation, and degradation (5-8). 
These aforementioned mechanisms are directed by two 
distinct RNA-binding factors; microRNAs and RNA-
binding proteins (RBPs) (9). While both microRNA 
and RBPs play a role in posttranscriptional regulation, 
the focus of this review is on the current understanding 
of RBP regulation of p53, p53 family members, and p53 
downstream targets. For a detailed review on p53 regulation 
by microRNA please see (10). Multiple cancer related 
proteins, including tumor suppressors and oncoproteins, are 
tightly controlled through translational regulation and/or 
mRNA half-life, emphasizing the influence of RBPs on the 
expression of cancer associated proteins (5,11). Translation, 
as well as mRNA decay, is typically influenced by RBPs 
interacting with target gene transcripts. Characteristically, 
the sequences in the mRNA that modulate translation and 
mRNA stability usually reside in the 5'- and 3'-untranslated 
regions (UTRs).
Structurally, RBPs possess a high proportion of 
modularity, as seen by the majority of RBPs containing at 
least one or more RNA-binding and auxiliary domains (12). 
The differential combination and arrangements of these 
RNA-binding modules assist in the numerous interactions 
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and regulatory abilities of these RBPs [reviewed here (13)]. 
To date, numerous classes of RNA-binding motifs have 
been identified including, RNA recognition motif (RRM), 
hnRNP K homology (KH) motif, RGG box, Pumilio, 
and double-stranded RNA-binding motif (13,14). Since 
many disease associated proteins are subjected to rigorous 
posttranscriptional regulation, it is without surprise that 
aberrant expression of RBPs have been tied to several 
human diseases including, neurological disorders, muscle 
atrophies, and cancer (11,15). Numerous RBPs have been 
linked with tumorigenesis (7). For example, aberrant eIF4E 
(eukaryotic translation initiation factor 4E) expression 
has been shown to lead to malignant transformation in 
mouse and rat fibroblasts (16), and further, targeting 
eIF4E with a cell-penetrating peptide leads to cell death 
in multiple cancer cell lines (17). Another important RBP 
in cancer, human antigen R (HuR), was one of the earliest 
RBPs identified to be aberrantly expressed in human 
malignances, including mammary and colon cancers (18,19). 
Extensive studies over the past decade revealed that HuR 
has the ability to induce the stability of many cancer-
related transcripts including cytokines, growth factors, 
invasion factors, and other proto-oncogenes [for a review 
of HuR in cancer please see (20)]. Collectively, various 
lines of evidence have come to light establishing that 
posttranscriptional regulation by RBPs may play a role in 
multiple human diseases including cancer. 
Regulation of p53
p53 is a transcription factor with an essential role in 
conserving the overall integrity of the genome and aiding 
in the prevention of cancer development. Highlighting 
the necessity for p53 in inhibiting tumorigenesis is the 
evidence that p53 inactivation occurs in more than 50% 
of human cancers (21). Under normal circumstances, p53 
is highly regulated and protein expression is kept at low 
levels. However, in reaction to stress stimuli, p53 is activated 
and functions as a robust transcription factor inducing the 
activation of downstream targets that function in DNA repair, 
cell-cycle arrest and apoptosis (22-24). The importance of 
strict p53 protein regulation is underscored by the fact that 
too much p53 leads to premature ageing (25) and cell death 
due to excessive apoptosis (26), whereas too little p53 has 
been shown to be a key aspect of tumorigenesis (27).
Most  work on the regulat ion of  p53 has  been 
demonstrated to be through posttranslational modifications, 
such as acetylation and phosphorylation. For example, 
phosphorylation of p53’s Ser15 (mouse Ser18) and Ser20 
(mouse Ser23) at its N-terminus is believed to stabilize 
p53 by blocking its interactions with a key p53 inhibitor, 
MDM2 (28). Furthermore, in response to stress stimuli, p53 
acquires increased acetylation correlating with increased 
p53 stabilization and activation (29-31). Subsequent studies 
revealed that not only were acetylation and phosphorylation 
important for regulating p53 stability and function, but 
other posttranslational modifications such as methylation, 
sumoylation, neddylation and ubiquitination were also 
able to modulate p53’s function and stability (32). Besides 
posttranslational modifications, it  is now starting 
to be understood that p53 is also regulated through 
posttranscriptional mechanisms.
To date, multiple RBPs have been found to regulate 
p53 translation by interacting with the 5' or 3' UTR of 
p53 mRNA. An RBP extensively studied in our laboratory, 
RBM38, also known as RNPC1, was determined to be 
a target of p53, and a key regulator of p53 expression. 
Over-expression of RBM38 inhibits, while knockdown 
of RBM38 increases, p53 translation in both basal and 
stress conditions (33). The inhibition of p53 translation 
was attributed to RBM38 interacting with p53 5' and 
3' UTRs. Upon binding to p53 mRNA, RBM38 is able 
to interact with eIF4E. As an essential component of 
mammalian translation, eIF4E binds to the 5' mRNA cap 
leading to the start of translation. The physical interaction 
between RBM38 and eIF4E causes the dissociation 
of eIF4E from p53 5' UTR, subsequently leading to 
decreased p53 translation. Furthermore, we demonstrated 
that phosphorylation of RBM38 at Ser195 modulates its 
ability to regulate p53 translation (Figure 1A). RBM38 
phosphorylation by glycogen synthase kinase 3 (GSK3) 
enhances p53 translation by removing the RBM38 
interaction with eIF4E, inducing p53 translation (34). 
Additionally, PPM1D phosphatase, a target of both p53 and 
RBM38, causes decreased phosphorylation of RBM38 at 
Ser195 leading to decreased p53 translation, as represented 
in Figure 1A (35). Physiologically, loss of RBM38 in 
mouse embryonic fibroblasts increased p53 protein levels 
triggering elevated premature senescence (36). RBM38 
was additionally shown to be frequently elevated in dog 
lymphomas, often correlating with decreased expression of 
wild-type p53, emphasizing a novel auto-regulatory loop 
between p53 and a target RBP. The RBM38-p53 axis is not 
the only p53 target RBP autoregulation discovered thus 
far. For example, wild-type p53 induced gene 1 (WIG-1), 
a known p53 target and double-stranded-RNA-binding 
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zinc finger protein, was shown to stabilize p53 mRNA by 
interacting with an AU-rich element (ARE) in p53 3' UTR 
leading to increased p53 expression in both normal and 
stressed cells (37). 
Besides RBM38, various other RBPs have been revealed 
to regulate p53 translation. For example, ribosomal protein 
L26 (RPL26) augments p53 translation after DNA damage 
by interacting with a stem loop formed by p53 5' and 3' 
UTRs. RPL26 binding to p53 mRNA leads to an enhanced 
association with heavier polysomes, ultimately increasing 
p53 translation. The increased p53 translation results in 
G1 cell-cycle arrest and heightened irradiation-induced 
apoptosis (38). Another RBP, polypyrimidine tract-binding 
protein (PTB), a p53 internal ribosome entry site (IRES) 
interacting trans-acting factor, differentially controls the 
expression of p53 isoforms by preferentially binding to both 
p53 IRES elements (39). Moreover, HuR binds to target 
mRNAs with AREs and has been shown to modulate p53 
translation via multiple approaches. HuR enhanced p53 
translation in RKO cells treated with UVC by binding to 
the 3' UTR of p53 mRNA, whereas decreased HuR protein 
levels reduced p53 translation (40). Alternatively, HuR was 
demonstrated to induce p53 translation via von Hippel-
Lindau (VHL)-dependent binding to p53 3' UTR (41), 
and further, in polyamine-depleted intestinal epithelial 
cells, HuR enhanced p53 mRNA stability (42). The above 
mentioned studies highlight the intricacy of HuR-mediated 
p53 expression. Like RBM38, other RBPs have been shown 
to inhibit p53 translation. For example, nucleolin competes 
with RPL26 to bind to p53 mRNA leading to decreased p53 
translation. Over-expression of nucleolin subdued, whereas 
reduced endogenous nucleolin levels enhanced, IR-mediated 
p53 translation (38). Furthermore, thymidylate synthase 
binds to the C-terminal coding region of p53 mRNA 
leading to suppressed p53 translation (43). Interestingly, 
our laboratory recently demonstrated that PCBP4, a 
KH domain containing RBP and target of p53 (44), 
indirectly regulates p53 protein levels by modulating the 
mRNA stability of ZNF709. Knockout of PCBP4 led to 
increased ZNF709 protein expression ultimately leading 
to decreased p53 via a proteasome-dependent degradation 
pathway (45). These lines of evidence further solidify the 
overwhelming complexity of p53 regulation and open up 
the possibility for potential therapeutic intervention by 
modulating the regulation of p53 by RBP’s. 
Regulation of p53 family member’s p63 and p73
Years after the discovery of p53, two highly homologous 
p53 family members were discovered, p63 and p73. 
With the discovery of p63 in 1997, and p73 in 1998, 
initial thoughts were that these two family members may 
share similar tumor suppressor functions to p53 (46-49). 
However, while p63 harbors many p53-like attributes, such 
as inducing cell-cycle arrest, senescence and apoptosis, 
p63 is not a classic tumor suppresser, but rather, has been 
shown to be critical for proper development (50,51). Of 
interest, p63 is expressed as two isoforms, TAp63 and 
ΔNp63. Subsequent studies have demonstrated that TAp63 
may function as a tumor suppressor promoting cell cycle 
arrest, senescence, and apoptosis (52). However, ΔNp63 
acts as an oncogene, with the ability to bind p53-responisve 
promoters, leading to repressed gene expression of p53 
targets (53). Further, ΔNp63α is frequently over-expressed 
in low-grade squamous cell carcinomas mostly attributed to 
chromosomal amplification (54). Likewise, p73 is expressed 
as two isoforms, TAp73 and ΔNp73. TAp73 functions 
as a tumor suppressor capable of inducing apoptosis and 
cell cycle arrest. Similar to ΔNp63, ΔNp73 may act as an 
oncogene inhibiting both TAp73 and p53 functions (55). 
Figure 1 Multiple mechanisms of regulating the p53 network by 
RBM38. (A) Phosphorylation of RBM38 by GSK3 leads to increased 
p53 translation, whereas dephosphorylation of RBM38 by PPM1D 
causes decreased p53 translation; (B) RBM38 and HuR work 
together to increase p21 expression via mRNA stability. MDM2 
mRNA stability is increased by HuR but decreased by RBM38. 
GSK3, glycogen synthase kinase 3; HuR, human antigen R.
A
B
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Captivatingly, our group uncovered that RBM38 
negatively regulates p63 mRNA stability by interacting 
with AU-/U-rich elements in p63 3' UTR (56). In addition, 
our laboratory recently discovered that RBM24, which 
has high sequence homology to RBM38 (57), was able 
to bind multiple regions in p63 3' UTR, subsequently 
destabilizing the p63 transcript, leading to decreased p63 
protein expression (58). Contrastingly, it was revealed that 
PCBP1 positively regulates p63 transcript by interacting 
with a CU-rich element (CUE) in p63 3' UTR leading 
to increased p63 mRNA and protein levels (59). The 
p53 family member p73 is likewise regulated by multiple 
RBPs. For example, PCBP2 interacts with CUEs in p73 3' 
UTR causing increased p73 mRNA stability and increased 
protein expression (60). Of interest, RBM38 was also 
shown to be a p73 target, and capable of binding a CUE 
in p73 3' UTR leading to enhanced p73 mRNA stability, 
emphasizing a novel positive feedback regulation between 
the two genes (61). Underlining the complex regulation of 
p53 family members by RBPs is demonstrated by the ability 
for RBM38 to decrease p53 mRNA translation, inhibit p63 
expression via destabilization of its transcript, and promote 
p73 expression by increasing its mRNA stability. 
Regulation of MDM2
As a key regulator and downstream target of p53, 
MDM2 was first identified as having gene amplification 
on double-minute chromosomes in transformed mouse 
fibroblasts (62). Further studies soon discovered that 
MDM2 was overexpressed in multiple human cancers, 
such as soft tissue sarcomas and osteosarcomas (63-65). 
Interestingly, high expression levels of MDM2 has 
been correlated with increased genomic instability 
revealed by amplified chromosome breaks, aneuploidy 
or polyploidy (66). Importantly, MDM2 interacts with 
p53 forming a regulatory feedback loop, where p53 induces 
MDM2 expression, and MDM2 negatively regulates 
p53 function and protein levels (67). MDM2 has been 
demonstrated to repress p53 transcriptional activity and 
lead to p53 protein degradation through three modes of 
action: (I) conceal the p53 transactivation domain; (II) cause 
the shuttling of p53 out of the nucleus; (III) target p53 for 
degradation as an E3 ubiquitin ligase (68-71). 
A substantial amount of work has been done to unravel 
the regulatory mechanisms leading to increased MDM2 
expression in cancer cells. In addition to the regulation by 
p53, multiple cancer cell lines exhibit enhanced MDM2 
protein translation, such as cutaneous melanoma cells, 
breast cancer cells, and Burkitt’s lymphoma, underlining 
one potential mechanism for increased MDM2 protein 
levels (72-74). MDM2 transcription is under the control of 
two distinct promoters, P1 and P2 (75,76). Eloquent studies 
demonstrated that the P1 promoter, upstream of the first 
exon is responsible for the control of the basal expression of 
MDM2, whereas the P2 promoter located in the first intron 
is responsible for the inducible expression of MDM2. While 
both promoters encode identical transcripts, the translation 
efficiency due to differences in their 5' UTR is where they 
differ. The transcript from the P1 promoter contains two 
upstream open reading frames and was shown to have 
lower translation efficacy. Contrastingly, the 5' UTR from 
the P2 promoter was determined to be shorter allowing 
for efficient translation (75,76). Further, the Ras-driven 
Raf/MEK/MAP kinase pathway was discovered to induce 
MDM2 in a p53-independent fashion via activation of Ets 
and AP-1 sites in the P2 promoter (77).
MDM2 is also post-transcriptionally regulated by 
multiple RBPs. For example, our laboratory has reported 
that RBM38 influences MDM2 post-transcriptionally. 
Overexpression of RBM38 led to decreased MDM2 
transcript and protein levels independent of p53 as 
represented in Figure 1B (78). This regulation was 
determined to be the result of RBM38 destabilizing MDM2 
mRNA by binding to multiple AU-/U-rich elements in 
MDM2 3' UTR. With interest, HuR was discovered to be 
able to interact with, and stabilize, MDM2 mRNA (79). In 
addition, HuR is positively regulated by RBM38 via mRNA 
stability (80). Added, in a regulatory feedback loop, MDM2 
interacts with, and stabilizes, HuR via MDM2-mediated 
NEDDylation, sequestering HuR in the nucleus protecting 
HuR from degradation (81). Both HuR and MDM2 
contrastingly regulate p53, and stabilize each other, adding 
further complexity to the p53 regulation by RBPs. Further, 
BCR/ABL-expressing myeloid precursor cells showed 
enhanced MDM2 mRNA translation that required the 
interaction of the LA antigen with a 27-nucleotide segment 
in MDM2 5' UTR. Suppressing La by siRNA resulted in 
decreased MDM2 expression and heightened susceptibility 
to drug-induced apoptosis (82). Additionally, extensive work 
has revealed that numerous ribosomal proteins regulate 
MDM2, thus modulating p53 proteins levels (83). This 
intricate network of regulatory feedback between p53 and 
p53 targets with RBPs becomes more apparent as shown 
by the aforementioned regulations of the RBM38/MDM2/
HuR/p53 axis.
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Regulation of p21
A number of p53 targets are implicated in inhibiting 
tumorigenesis. For example, p21, a key regulator of p53 
involved in cell cycle arrest, belongs to the Cip and Kip 
family of cyclin-dependent kinases (CDK) inhibitors. As a 
CDK inhibitor, p21 was discovered to be a major regulator 
in cell cycle transition from G1 to S by inhibiting the kinase 
activity of CDK2 and CDK1 (also known as CDC2) (84). 
Further, p21 directly interacts with proliferating cell nuclear 
antigen (PCNA), leading to decreased PCNA-dependent 
DNA polymerase activity, consequently inhibiting DNA 
replication and adversely affecting other PCNA-dependent 
DNA repair processes (85,86). Interestingly, p21 was shown 
to be a master regulator of multiple tumor suppressor 
pathways that were revealed to be independent of the p53 
tumor suppressor pathway (87). 
In addition to the regulation by the p53 family, p21 
is regulated by multiple p53-independent mechanisms 
(46,50,84,88) [for a comprehensive review please see (89)]. 
For example, the signaling through the Ras GTPase 
induces, whereas signaling through the Rho GTPase 
inhibits, p21 transcription (90). This transactivation of 
p21 through Ras signaling was later revealed to require 
the transcription factor E2F1 (91). Heterogeneous nuclear 
ribonucleoprotein K (hnRNP K) was also shown to 
specifically bind to CUEs in p21 3' UTR leading to p21 
translational repression (92). Like p53, p21 is positivity 
regulated by HuR. HuR interacts with the 3' UTR of p21 
mRNA causing increased inducibility and half-life of the 
p21 transcript (93). Further, RBM38 stabilizes both the basal 
and stress-induced p21 transcripts by directly binding to 
the 3' UTR of p21 mRNA (94). Increasing the complexity 
of p21 regulation by RBM38, it was later discovered that 
RBM38 and HuR physically interact and preferentially 
bind the upstream and downstream AREs in p21 3' UTR, 
respectively (95). Additionally, the RNA-binding activity 
of HuR to the p21 transcript was enhanced with increased 
RBM38 protein expression, suggestion a cooperative 
regulation of p21 by both RBPs as demonstrated in 
Figure 1B. Our group additionally established that RBM24 
was able to interact with an AU/U rich region located 
in p21 3' UTR heightening p21 expression (57). PCBP1 
and PCBP2 have also been revealed to cause decreased 
p21 mRNA stability via interaction with its 3' UTR (96). 
Moreover, PCBP4 was proven by our group to negatively 
regulate the p21 transcript. In PCBP4-deficient mice, it was 
discovered that p21 expression was noticeably enhanced, 
and this regulation by PCBP4 was due to its binding to p21 
3' UTR, negatively regulating p21 mRNA stability (97). 
Collectively, the reciprocal regulation of p53, and p53 
targets, by RBPs is indeed complex. Recapitulated by the 
p53/HuR/RBM38/p21 regulatory axis, this adds further 
credence for the additional study of the posttranscriptional 
regulation of p53 and downstream targets by RBPs.
Conclusions and perspectives 
In light of recent works, the significance of gene regulation 
via posttranscriptional regulation has been revealed to not 
only regulate p53, but that of p53 family members and 
downstream targets. Until recently, most emphasis has 
been put towards understanding the transcriptional and 
posttranslational modifications dictating p53 function and 
downstream pathways. However, as highlighted in this 
review, an increased understanding of the posttranscriptional 
regulation of p53 and p53 targets will surely be needed 
to appreciate the role of p53 in tumor suppression, and 
subsequently, in the development of p53-based therapies. 
Herein, we reiterated the ability for multiple RBPs to 
regulate p53, and p53 pathways. While it is now understood 
that p53 and p53 targets are regulated by RBPs, the 
reciprocal regulation of these RBPs in a regulatory feed-back 
loop with p53 is just now starting to be revealed.
Even though the last 30 years of research have uncovered 
an enormous amount of detail about the biology of p53, 
nonetheless, numerous questions about p53 regulation 
continually reappear in a new context. With the exciting 
findings of the reciprocal regulation of p53 by RBPs, 
such as the RBM38/HuR/MDM2/p53 regulatory loop, 
our knowledge of the complex regulation of p53 and the 
p53 network allows for the potential intervention with 
therapeutic approaches to upregulate the expression of p53, 
or p53 targets like p21. For example, as depicted in Figure 1, 
the regulatory network by RBM38 is multifaceted. RBM38 
is induced by p53 and negatively effects p53 translation, 
while also adversely affecting MDM2, a key regulator of p53. 
Further, HuR upregulates p53, but also increases MDM2 
translation. In addition, RBM38 and HuR cooperatively 
influence p21 mRNA stability increasing its expression. 
One could imagine, with a therapeutic application, that 
by removing the inhibition of RBM38 on p53, this would 
lead to an increase in both p53 and p21, potentially 
inducing tumor suppression. Blocking RBM38 from 
binding to p53 mRNA using oligonucleotides, or inhibiting 
the interaction between RBM38 and eIF4E via small 
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competing peptides are two possible approaches aimed at 
modulating RBM38 regulation of p53. Importantly, RBM38 
deficiency was shown to decrease tumor penetrance in mice 
heterozygous for p53 by enhancing p53 expression (36). 
Accumulating research into RBPs is continually revealing 
new RBPs and targets, while many questions still remain 
unanswered. For example, with increasing evidence that 
multiple RBPs are capable of regulating a single target, 
how is this regulation synchronized? Further, is there a 
reciprocal coordination between p53 and RBPs to regulate 
mutual targets, such as p21 or MDM2? Nonetheless, 
additional work is needed to garnish the knowledge of the 
intricate regulation of p53 and p53 family members with the 
hope of devising potential therapeutic approaches targeting 
RBPs.
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